Manufacturer of Controlled Substances; Notice of Application; R & D Systems, Inc., 47110-47111 [2012-19193]

Agencies

• Drug Enforcement Administration
• Department of Justice

[Federal Register Volume 77, Number 152 (Tuesday, August 7, 2012)]
[Notices]
[Pages 47110-47111]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-19193]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application; R & 
D Systems, Inc.

    Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this 
is notice that on May 4, 2012, R & D Systems, Inc., 614 McKinley Place 
NE., Minneapolis, Minnesota 55413, made application to the Drug 
Enforcement Administration (DEA) for registration as an importer of the 
following basic classes of controlled substances:

------------------------------------------------------------------------
                       Drug                               Schedule
------------------------------------------------------------------------
1-Pentyl-3-(1-naphthoyl)indole (7118)............  I
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-               I
 hydroxycyclohexyl]-phenol (7297).
Marihuana (7360).................................  I
Tetrahydrocannabinols (7370).....................  I
4-Bromo-2,5-dimethoxyamphetamine (7391)..........  I
3,4-Methylenedioxymethamphetamine (7405).........  I
Dimethyltryptamine (7435)........................  I
Amphetamine (1100)...............................  II
Methylphenidate (1724)...........................  II
Phencyclidine (7471).............................  II
Cocaine (9041)...................................  II
Oxycodone (9143).................................  II
Thebaine (9333)..................................  II
Fentanyl (9801)..................................  II
------------------------------------------------------------------------

    The company plans to import the listed controlled substances in 
dosage form to distribute to researchers.
    In reference to drug codes 7360 and 7370, the company plans to 
import a synthetic cannabidiol and a synthetic Tetrahydrocannabinol. No 
other activity for this drug code is authorized for this registration.
    The import of the above listed basic classes of controlled 
substances would be granted only for analytical testing and clinical 
trials. This authorization does not extend to the import of a finished 
FDA approved or non-approved dosage form for commercial distribution in 
the United States.
    Any bulk manufacturer who is presently, or is applying to be, 
registered with DEA to manufacture such basic classes of controlled 
substances listed in schedules I or II, which fall under the authority 
of section 1002(a)(2)(B) of the Act 21 U.S.C. 952(a)(2)(B) may, in the 
circumstances set forth in 21 U.S.C. 958(i), file comments or 
objections to the issuance of the proposed registration and may, at the 
same time, file a written request for a hearing on such application 
pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 
1316.47.
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than September 6, 2012.
    This procedure is to be conducted simultaneously with, and 
independent of, the procedures described in 21 CFR Sec.  1301.34(b), 
(c), (d), (e), and (f). As noted in a previous notice published in the 
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants 
for registration to import a basic class of any controlled substances 
in schedules I or II are, and will continue to be, required to 
demonstrate to the Deputy Assistant Administrator, Office of Diversion 
Control, Drug Enforcement Administration, that the requirements for 
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 
21

[[Page 47111]]

CFR Sec.  1301.34(b), (c), (d), (e), and (f) are satisfied.

    Dated: July 31, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2012-19193 Filed 8-6-12; 8:45 am]
BILLING CODE 4410-09-P